C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has been given a consensus rating of “Hold” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.71.
A number of equities research analysts have recently commented on the stock. Wells Fargo & Company upped their target price on shares of C4 Therapeutics from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Thursday, May 9th. Stifel Nicolaus upped their price objective on C4 Therapeutics from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 9th.
Read Our Latest Research Report on CCCC
Institutional Inflows and Outflows
C4 Therapeutics Trading Up 0.6 %
Shares of NASDAQ CCCC opened at $6.54 on Tuesday. The stock has a market cap of $450.02 million, a P/E ratio of -2.76 and a beta of 3.07. C4 Therapeutics has a twelve month low of $1.06 and a twelve month high of $11.88. The stock has a 50 day moving average of $5.19 and a two-hundred day moving average of $6.66.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, meeting the consensus estimate of ($0.41). The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $10.93 million. C4 Therapeutics had a negative net margin of 629.24% and a negative return on equity of 52.85%. As a group, research analysts predict that C4 Therapeutics will post -1.56 earnings per share for the current year.
About C4 Therapeutics
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
See Also
- Five stocks we like better than C4 Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- Survey: Top 175 Fittest Retirement Locations in America
- What is the FTSE 100 index?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.